1-3 of 3
Antje Wegener, MD
Close
Sort by
Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD
Journal: Blood
Blood (2013) 122 (21): 1018.
https://doi.org/10.1182/blood.V122.21.1018.1018
Published: 2013
Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD
Journal: Blood
Blood (2013) 122 (21): 2257.
https://doi.org/10.1182/blood.V122.21.2257.2257
Published: 2013
Journal Articles

Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia

Antonio Piga, MD, Silvia Fracchia, MD, Maria Eliana Lai, MD, M Domenica Cappellini, MD, Dany Habr, MD, Antje Wegener, MD, Emmanuel Bouillaud, MSc, Gian Luca Forni, MD
Journal: Blood
Blood (2012) 120 (21): 3257.
https://doi.org/10.1182/blood.V120.21.3257.3257
Published: 2012